Poolbeg Pharma PLC

POLB 001 LPS Challenge Trial Data to be Presented at IUIS

By Alex Langton | 9 November 2023

Elric and I have a financial interest in Poolbeg Pharma.

Poolbeg Pharma, a company at the forefront of developing innovative therapeutics for diseases with substantial unmet medical needs, has announced a pivotal moment in its research trajectory. An abstract elucidating the potential of POLB 001, a promising therapeutic candidate, has been accepted for presentation at the prestigious 18th International Congress of Immunology (IUIS), scheduled from 27 November to 2 December 2023, in Cape Town, South Africa. This event, renowned as the zenith of immunological discourse, assembles the crème de la crème of the immunology world, including eminent academic scholars, leading healthcare practitioners, independent research entities, and industry vanguards.